Nanocellect Biomedical Inc.

Nanocellect Biomedical Inc. is a for-profit biotechnology company located in San Diego, California, specializing in advanced cell analysis, sorting, and dispensing equipment and services. The company is registered in SAM.gov and has been actively providing sophisticated scientific instrumentation to federal agencies since 2009. Its primary product line centers on the WOLF G2 Cell Sorter and N1 Single Cell Dispenser, which are microfluidic-based technologies designed for biomedical research, drug development, and scientific investigation. These innovative instruments enable researchers to perform precise cell sorting, analysis, and single-cell isolation across various scientific domains.

Nanocellect Biomedical Inc. has an extensive federal contract portfolio spanning multiple agencies, including the National Institutes of Health, Centers for Disease Control and Prevention, Environmental Protection Agency, Department of Veterans Affairs, Department of Agriculture, and Department of Defense. The company's contract awards primarily involve providing cell sorter systems, maintenance agreements, and related accessories, with contract values ranging from $13,750 to $248,480. Most contracts were awarded without specific set-aside designations, though a few were designated for small businesses. The contracts typically involve delivering specialized cell sorting equipment like the WOLF G2 Cell Sorter, often with specific applications such as supporting research in genetics, cardiovascular science, neurology, and infectious disease studies. Notably, the company has been recognized as the original equipment manufacturer (OEM) for its cell sorting technology, which has made it a sole-source provider for several federal procurement efforts.

Nanocellect Biomedical Inc. has received at least one significant federal grant award from the National Institute of General Medical Sciences, a $2.6 million project grant focused on developing an AI-aided tool for biopharmaceutical cell line development. This grant, running from August 2022 to July 2024, aims to create an innovative system for rapidly identifying and isolating high-performance cells for monoclonal antibody drug development. The proposed tool leverages advanced technologies including a 3D imaging flow cytometer, a cell placement module, and a convolutional neural network to classify individual cells immediately after genetic modification. The grant's objectives include dramatically shortening clone selection timelines from 6 weeks to 2-3 days and increasing the number of analyzable valuable clones by 50 times, with potential implications for saving drug development costs and accelerating protein-based therapeutic and vaccine production.